Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12922895 | 0.86 | GLS (0.61) | KDM4EALDH1A1ROCK1SMN1; SMN2EPHX2 | |
| SCHEMBL13849595 | 0.83 | KDM1A (0.55) | KDM4EALDH1A1SMN1; SMN2LTA4HSIGMAR1 | |
| SCHEMBL13849609 | 0.82 | ROCK1 (0.44) | KDM4EALDH1A1ROCK1SMN1; SMN2EPHX2 | |
| SCHEMBL28588436 | 0.80 | KMT2A (0.55) | KDM4EALDH1A1ROCK1SMN1; SMN2ROCK2 | |
| Hydrochloric Acid SCHEMBL4576942 | 0.79 | GLS (0.54) | SIGMAR1GLS | |
| SCHEMBL27354500 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1ROCK1EPHX2ROCK2 | |
| SCHEMBL8785521 | 0.79 | ALDH1A1 (0.61) | KDM4EALDH1A1SMN1; SMN2LTA4HDRD2 | |
| SCHEMBL5231666 | 0.78 | ALDH1A1 (0.65) | KDM4EALDH1A1LTA4HEPHX2DRD2 | |
| SCHEMBL13865082 | 0.78 | KDM4E (0.56) | KDM4EALDH1A1ROCK1SMN1; SMN2LTA4H | |
| SCHEMBL14025019 | 0.77 | SIGMAR1 (0.48) | SMN1; SMN2SIGMAR1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | KDM4E 2809/4885ALDH1A1 115/4885ROCK1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.